Phase II trial of elliptinium in advanced renal cell carcinoma.
Forty patients with advanced renal cell carcinoma were treated with elliptinium by a weekly infusion of 100 mg/m2. Of 38 evaluable patients, five had an objective response (13.2%). Average response duration was 8 months (range, 5-11). The major dose-limiting toxic effect was induction of antielliptinium antibodies, with the risk of intravascular hemolysis. Elliptinium has modest activity in advanced renal cell cancer and does not produce myelosuppression.
D000328:Adult; D000368:Aged; D000470:Alkaloids / Q000627:therapeutic use*; D000906:Antibodies / Q000032:analysis; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D004341:Drug Evaluation; D004611:Ellipticines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000470:Alkaloids; D000906:Antibodies; D000970:Antineoplastic Agents; D004611:Ellipticines; C027767:elliptinium